The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Comparison of the Effect of Mutant and Wild-Type p53 on Global Gene Expression
Published version of a preprint
Abstract
The mechanisms for “gain-of-function” phenotypes produced by mutant p53s such as enhanced proliferation, resistance to transforming growth factor-β–mediated growth suppression, and increased tumorigenesis are not known. One theory is that these phenotypes are caused by novel transcriptional regulatory events acquired by mutant p53s. Another explanation is that these effects are a result of an imbalance of functions caused by the retention of some of the wild-type transcriptional regulatory events in the context of a loss of other counterbalancing activities. An analysis of the ability of DNA-binding domain mutants A138P and R175H, and wild-type p53 to regulate the expression levels of 6.9 × 103 genes revealed that the mutants retained only <5% of the regulatory activities of the wild-type protein. A138P p53 exhibited mostly retained wild-type regulatory activities and few acquired novel events. However, R175H p53 possessed an approximately equal number of wild-type regulatory events and novel activities. This is the first report that, after examination of the regulation of a large unfocused set of genes, provides data indicating that remaining wild-type transcriptional regulatory functions existing in the absence of counterbalancing activities as well as acquired novel events both contribute to the gain-of-function phenotypes produced by mutant p53s. However, mutant p53s are likely to be distinct in terms of the extent to which each mechanism contributes to their gain-of-function phenotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“WT TP53 generally exhibits a high affinity for specific DNA sequences, crucial for its tumor suppressor activity, whereas mutations within DBD reduce or eliminate such DNA-binding ability in the promoters of certain genes 45.”
From Combined Point Mutation in a Single Allele of the TP53 Gene Potentiates the Oncogenic and Transcriptional Properties of TP53 in Lung Cancer (2026) · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Repression of RNA Polymerase I Transcription by the Tumor Suppressor p53
Zhai, W., & Comai, L. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.16.5930-5938.2000 · Cited by 289
Research works printed but not linked: 57
- Oren M Decision making by p53: life, death and cancer. Cell Death Differ 2003; 10: 431-42. · DOI · Paper page
- Prives C, Hall PA The p53 pathway. J Pathol 1999; 187: 112-26. · doi:10.1002/(sici)1096-9896(199901)187:1<112::aid-path250>3.0.co;2-3
- May P, May E Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 1999; 18: 7621-36. · DOI · Paper page
- Hainaut P, Hollstein M p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000; 77: 81-137. · DOI · Paper page
- Beroud C, Soussi T p53 gene mutation: software and database. Nucleic Acids Res 1998; 26: 200-4. · DOI
- Hollstein M, Moeckel G, Hergenhahn M, et al On the origins of tumor mutations in cancer genes: insights from the p53 gene. Mutat Res 1998; 405: 145-54. · DOI
- Woods DB, Vousden KH Regulation of p53 function. Exp Cell Res 2001; 264: 56-66. · DOI · Paper page
- van Oijen MG, Slootweg PJ Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res 2000; 6: 2138-45.
- Bullock AN, Henckel J, Fersht AR Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 2000; 19: 1245-56. · DOI · Paper page
- Chen Y, Chen PL, Lee WH Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle. Mol Cell Biol 1994; 14: 6764-72. · DOI
- Hsiao M, Low J, Dorn E, et al Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol. 1994; 145: 702-14.
- Gerwin BI, Spillare E, Forrester K, et al Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1. Proc Natl Acad Sci USA 1992; 89: 2759-63. · DOI
- Wang XJ, Greenhalgh DA, Jiang A, et al Analysis of centrosome abnormalities and angiogenesis in epidermal-targeted p53172H mutant and p53-knockout mice after chemical carcinogenesis: evidence for a gain of function. Mol Carcinog 1998; 23: 185-92. · DOI
- Lanyi A, Deb D, Seymour RC, Ludes-Meyers JH, Subler MA, Deb S “Gain of function” phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence- specific nucleic acid-binding domain. Oncogene 1998; 16: 3169-76. · DOI
- Shaulsky G, Goldfinger N, Rotter V Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res 1991; 51: 5232-7.
- Cardinali M, Kratochvil FJ, Ensley JF, Robbins KC, Yeudall WA Functional characterization in vivo of mutant p53 molecules derived from squamous cell carcinomas of the head and neck. Mol Carcinog 1997; 18: 78-88. · doi:10.1002/(sici)1098-2744(199702)18:2<78::aid-mc3>3.0.co;2-m
- Hixon ML, Flores A, Wagner M, Gualberto A Gain of function properties of mutant p53 proteins at the mitotic spindle cell cycle checkpoint. Histol Histopathol 2000; 15: 551-6.
- Gualberto A, Aldape K, Kozakiewicz K, Tlsty TD An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci USA 1998; 95: 5166-71. · DOI · Paper page
- Blandino G, Levine AJ, Oren M Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999; 18: 477-85. · DOI · Paper page
- Reiss M, Vellucci VF, Zhou ZL Mutant p53 tumor suppressor gene causes resistance to transforming growth factor beta 1 in murine keratinocytes. Cancer Res 1993; 53: 899-904.
- Beckwith M, Ruscetti FW, Sing GK, Urba WJ, Longo DL Anti-IgM induces transforming growth factor-beta sensitivity in a human B-lymphoma cell line: inhibition of growth is associated with a downregulation of mutant p53. Blood 1995; 85: 2461-70. · doi:10.1182/blood.v85.9.2461.bloodjournal8592461
- Frazier MW, He X, Wang J, Gu Z, Cleveland JL, Zambetti GP Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol 1998; 18: 3735-43. · DOI · Paper page
- Ueba T, Nosaka T, Takahashi JA, et al Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. Proc Natl Acad Sci USA 1995; 91: 9009-13. · DOI
- Werner H, Karnieli E, Rauscher FJ, LeRoith D Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 1996; 93: 8318-23. · DOI · Paper page
- Margulies L, Sehgal PB Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBP beta (NF-IL6) activity by p53 species. J Biol Chem 1993; 268: 15096-100. · DOI
- Ludes-Meyers JH, Subler MA, Shivakumar CV, et al Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol Cell Biol 1996; 16: 6009-19. · DOI · Paper page
- Blagosklonny MV p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect. FASEB J 2000; 14: 1901-7. · DOI · Paper page
- Livak KJ, Schmittgen TD Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 2001; 25: 402-8. · DOI · Paper page
- Shimo T, Nakanishi T, Nishida T, et al Involvement of CTGF, a hypertrophic chondrocyte-specific gene product, in tumor angiogenesis. Oncology 2001; 61: 315-22. · DOI
- Shimo T, Kubota S, Kondo S, et al Connective tissue growth factor as a major angiogenic agent that is induced by hypoxia in a human breast cancer cell line. Cancer Lett 2001; 174: 57-64. · DOI
- Feinstein E, Gale RP, Reed J, Canaani E Expression of the normal p53 gene induces differentiation of K562 cells. Oncogene 1992; 7: 1853-7.
- Johnson P, Chung S, Benchimol S Growth suppression of Friend virus- transformed erythroleukemia cells by p53 protein is accompanied by hemoglobin production and is sensitive to erythropoietin. Mol Cell Biol 1993; 13: 1456-63. · DOI
- Kawamura M, Yamashita T, Segawa K, Kaneuchi M, Shindoh M, Fujinaga K The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity. Oncogene 1996; 12: 2361-7.
- Chin KV, Ueda K, Pastan I, Gottesman MM Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science (Wash D C) 1992; 255: 459-62. · DOI · Paper page
- Dittmer D, Pati S, Zambetti G, et al Gain of function mutations in p53. Nat Genet 1993; 4: 42-6. · DOI · Paper page
- Prowse DM, Bolgan L, Molnar A, Dotto GP Involvement of the Sp3 transcription factor in induction of p21Cip1/WAF1 in keratinocyte differentiation. J Biol Chem 1997; 272: 1308-14. · DOI
- Sowa Y, Orita T, Minamikawa-Hiranabe S, Mizuno T, Nomura H, Sakai T Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor. Cancer Res 1999; 59: 4266-70.
- Xiao H, Hasegawa T, Isobe K Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J Cell Biochem 1999; 73: 291-302. · DOI
- Xiao H, Hasegawa T, Isobe K p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor. J Biol Chem 2000; 275: 1371-6. · DOI · Paper page
- Sumi T, Nakatani T, Yoshida H, et al Expression of matrix metalloproteinases 7 and 2 in human renal cell carcinoma. Oncol Rep 2003; 10: 567-70. · doi:10.3892/or.10.2.345
- Tanioka Y, Yoshida T, Yagawa T, et al Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavorable prognosis in superficial oesophageal cancer. Br J Cancer 2003; 89: 2116-21. · doi:10.1038/sj.bjc.6601372
- Waas ET, Wobbes T, Lomme RM, DeGroot J, Ruers T, Hendriks T Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Br J Surg 2003; 90: 1556-64. · doi:10.1002/bjs.4346
- Lok IH, Briton-Jones CM, Yuen PM, Haines CJ Variable expression of oviductin mRNA at different stages of human reproductive cycle. J Assist Reprod Genet 2002; 19: 569-76. · doi:10.1016/s0015-0282(01)03216-2
- Lindsay LL, Wieduwilt MJ, Hedrick JL Oviductin, the Xenopus laevis oviductal protease that processes egg envelope glycoprotein gp43, increases sperm binding to envelopes, and is translated as part of an unusual mosaic protein composed of two protease and several CUB domains. Biol Reprod 1999; 60: 989-95. · DOI
- Yaron Y, Schwartz D, Evans MI, Aloni R, Kapon A, Rotter V p53 tumor suppressor gene expression in the mouse ovary during an artificially induced ovulatory cycle. J Reprod Med 1999; 44: 107-14.
- Jurisicova A, Latham KE, Casper RF, Varmuza SL Expression and regulation of genes associated with cell death during murine preimplantation embryo development. Mol Reprod Dev 1998; 51: 243-53. · DOI · Paper page
- Wu X, Bayle JH, Olson D, Levine AJ The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993; 7: 1126-32. · DOI · Paper page
- Kurdistani SK, Arizti P, Reimer CL, Sugrue MM, Aaronson SA, Lee SW Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. Cancer Res 1998; 58: 4439-44.
- Campomenosi P, Monti P, Aprile A, et al p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 2001; 20: 3573-9. · DOI
- Tsang WP, Chau SP, Fung KP, Kong SK, Kwok TT Modulation of multidrug resistance-associated protein 1 (MRP1) by p53 mutant in Saos-2 cells. Cancer Chemother Pharmacol 2003; 51: 161-6. · doi:10.1007/s00280-002-0551-2
- Kubicka S, Kuhnel F, Zender L, et al p53 represses CAAT enhancer-binding protein (C/EBP)-dependent transcription of the albumin gene. A molecular mechanism involved in viral liver infection with implications for hepatocarcinogenesis. J Biol Chem 1999; 274: 32137-44. · DOI
- Chesnokov I, Chu WM, Botchan MR, Schmid CW p53 inhibits RNA polymerase III-directed transcription in a promoter-dependent manner. Mol Cell Biol 1996; 16: 7084-8. · DOI
- Horikoshi N, Usheva A, Chen J, Levine AJ, Weinmann R, Shenk T Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression. Mol Cell Biol 1995; 15: 227-34. · DOI · Paper page
- Chicas A, Molina P, Bargonetti J Mutant p53 forms a complex with Sp1 on HIV-LTR DNA. Biochem Biophys Res Commun. 2000; 279: 383-90. · DOI
- Ho J, Benchimol S Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ 2003; 10: 404-8. · DOI · Paper page
- Sun Y, Wenger L, Rutter JL, Brinckerhoff CE, Cheung HS p53 down-regulates human matrix metalloproteinase-1 (Collagenase-1) gene expression. J Biol Chem 1999; 274: 11535-40. · DOI
- Cairns CA, White RJ p53 is a general repressor of RNA polymerase III transcription. EMBO J 1998; 17: 3112-23. · DOI · Paper page
Cited by
Sur, S., Pagliarini, R., Bunz, F., Rago, C., Diaz, L. A., Kinzler, K. W., Vogelstein, B., & Papadopoulos, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813333106 · Cited by 295
Mutant p53: an oncogenic transcription factor
Strano, S., Dell'Orso, S., Di Agostino, S., Fontemaggi, G., Sacchi, A., & Blandino, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210296 · Cited by 269
Lanni, C., Masi, M., Racchi, M., & Govoni, S. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0760-2 · Cited by 130
p53 at the crossroads between cancer and neurodegeneration
Lanni, C., Racchi, M., Memo, M., Govoni, S., & Uberti, D. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.02.034 · Cited by 95
Junk, D. J., Vrba, L., Watts, G. S., Oshiro, M. M., Martinez, J. D., & Futscher, B. W. (2008) · Neoplasia · doi:10.1593/neo.08120 · Cited by 74
Metadata
- Authors
- O’Farrell, T. J., Ghosh, P., Dobashi, N., Sasaki, C. Y., & Longo, D. L.
- Affiliations
- Laboratory of Immunology, Gerontology Research Center, National Institute on Aging, NIH, Baltimore, Maryland
- Venue
- Cancer Research
- Published
- 2004-11-15
- Volume
- 64
- Issue
- 22
- Pages
- 8199-8207
- ISSN
- 0008-5472
- 1538-7445
- Cited by
- 37
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of the Effect of Mutant and Wild-Type p53 on Global Gene Expression. https://app.cochat.ai/papers/10.1158/0008-5472.can-03-3639
- The paper
- O’Farrell, T. J., Ghosh, P., Dobashi, N., Sasaki, C. Y., & Longo, D. L. (2004). Comparison of the Effect of Mutant and Wild-Type p53 on Global Gene Expression. Cancer Research. https://doi.org/10.1158/0008-5472.can-03-3639
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.